StockData
Verrica Pharmaceuticals Inc. logo

Verrica Pharmaceuticals Inc. (VRCA) stock

VRCANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$3.20−0.36 (-10.11%)

Close on Nov 16, 2026Market cap $54.97MP/E –Yield –

Verrica Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Verrica Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $14.62M, up 89.8% year over year. For fiscal 2025 it was $8.86M, down 25.2% from the year before. The highest annual figure on record is $20.30M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$8.86M-25.2%
FY2024Dec 31, 2024$11.84M-41.7%
FY2023Dec 31, 2023$20.30M+66.4%
FY2022Dec 31, 2022$12.20M-23.4%
FY2021Dec 31, 2021$15.93M+1.6%
FY2020Dec 31, 2020$15.67M+1.5%
FY2019Dec 31, 2019$15.44M+20.3%
FY2018Dec 31, 2018$12.83M+243.9%
FY2017Dec 31, 2017$3.73M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$6.03M+226.9%
Q1 FY2026Mar 31, 2026$3.86M+69.0%
Q4 FY2025Dec 31, 2025$2.52M+115.8%
Q3 FY2025Sep 30, 2025$2.21M-8.3%
Q2 FY2025Jun 30, 2025$1.85M-44.4%
Q1 FY2025Mar 31, 2025$2.28M-53.8%
Q4 FY2024Dec 31, 2024$1.17M-78.0%
Q3 FY2024Sep 30, 2024$2.41M-63.1%
Q2 FY2024Jun 30, 2024$3.32M-42.0%
Q1 FY2024Mar 31, 2024$4.95M+80.6%
Q4 FY2023Dec 31, 2023$5.32M+75.7%
Q3 FY2023Sep 30, 2023$6.51M+134.2%
Q2 FY2023Jun 30, 2023$5.73M+45.2%
Q1 FY2023Mar 31, 2023$2.74M+12.0%
Q4 FY2022Dec 31, 2022$3.03M-9.8%
Q3 FY2022Sep 30, 2022$2.78M-26.1%
Q2 FY2022Jun 30, 2022$3.94M+14.4%
Q1 FY2022Mar 31, 2022$2.45M-54.4%
Q4 FY2021Dec 31, 2021$3.36M+47.8%
Q3 FY2021Sep 30, 2021$3.76M-24.6%
Q2 FY2021Jun 30, 2021$3.45M-2.1%
Q1 FY2021Mar 31, 2021$5.36M+9.6%
Q4 FY2020Dec 31, 2020$2.27M-42.8%
Q3 FY2020Sep 30, 2020$4.99M+63.6%
Q2 FY2020Jun 30, 2020$3.52M-10.4%
Q1 FY2020Mar 31, 2020$4.89M+9.0%
Q4 FY2019Dec 31, 2019$3.97M-19.2%
Q3 FY2019Sep 30, 2019$3.05M-12.1%
Q2 FY2019Jun 30, 2019$3.93M+11.7%
Q1 FY2019Mar 31, 2019$4.49M+384.0%
Q4 FY2018Dec 31, 2018$4.92M+339.8%
Q3 FY2018Sep 30, 2018$3.47M+209.6%
Q2 FY2018Jun 30, 2018$3.52M+259.8%
Q1 FY2018Mar 31, 2018$927.00K+80.0%
Q4 FY2017Dec 31, 2017$1.12M–
Q3 FY2017Sep 30, 2017$1.12M–
Q2 FY2017Jun 30, 2017$977.00K–
Q1 FY2017Mar 31, 2017$515.00K–

More Verrica Pharmaceuticals figures

See a number that looks wrong?